Targeted therapies in brain metastases

Current Treatment Options in Neurology

Volumn 16, Issue 1, 2014, Pages

  Lin, Nancy U ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Brain metastases; Breast cancer; Lung cancer; Melanoma; Renal cell carcinoma; Targeted therapies; Treatment

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DABRAFENIB; ERLOTINIB; GEFITINIB; IPILIMUMAB; LAPATINIB; SORAFENIB; SUNITINIB; VEMURAFENIB;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLEEDING; BRAIN DAMAGE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER THERAPY; COLITIS; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG CONTRAINDICATION; DRUG TARGETING; DRY SKIN; DYSPEPSIA; DYSPNEA; EPISTAXIS; FATIGUE; FEVER; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERKERATOSIS; HYPERTENSION; HYPOPHOSPHATEMIA; INTERSTITIAL LUNG DISEASE; LIMB PAIN; LIVER DISEASE; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CANCER; MULTIPLE METASTASIS; NAUSEA; PAPILLOMA; PERIPHERAL EDEMA; PHOTOSENSITIVITY; PROTEINURIA; PRURITUS; RASH; RECURRENT BRAIN METASTASIS; RHINITIS; SKIN DISCOLORATION; SKIN PAPILLOMA; STOMATITIS; SYSTEMIC THERAPY; TASTE DISORDER; VOMITING;

EID: 84891770347     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-013-0276-z     Document Type: Article

References (65)

1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865-72.
2. Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III nonsmall-cell lung cancer: A retrospective review by the Southwest Oncology Group. J ClinOncol. 2005;23(13):2955-61.
3. Olson EM, Najita JS, Burstein HJ, Sohl J, Arnaout A, Winer EP, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. The Breast. 2013;22(4):525-31.
4. Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: A retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013;14(3):244-8. This study describes the incidence of CNS metastases in patients with breast cancer who have relapsed after adjuvant trastuzumab. The study confirms the low incidence of CNS as site of first relapse but demonstrates that CNS recurrences over time remain extremely common, even in the posttrastuzumab era.
5. Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, et al. The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6(1):1-9.
6. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys. 2012;82(5):2111-7.
7. Soffietti R, Cornu P, Delattre JY, Grant R, Graus F, Grisold W, et al. EFNS Guidelines on diagnosis and treatment of brain metastases: Report of an EFNS Task Force. Eur J Neurol. 2006;13(7):674-81.
8. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. Central Nervous System Cancers. 2013. Available at: Www.nccn.org/professionals/physician-gls/pdf/cns. Accessed 1 Aug 2013.
9. Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012;2:210-25. This publication summarizes the American Society for Radiation Oncology evidence-based guidelines for management of newly diagnosed brain metastases and provides a good starting point for readers interested in understanding basic principles of standard current treatments.
10. Linskey ME, Kalkanis SN. Evidence-linked, clinical practice guidelines-getting serious; getting professional. J Neuro Oncol. 2010;96(1):1-5.
11. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494-500.
12. Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys. 1994;29(4):711-7.
13. Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78(7):1470-6.
14. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665-72.
15. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA. 2006;295(21):2483-91.
16. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy vs observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134-41. This publication reports the results of a randomized trial testing the contribution of WBRT after radiosurgery or surgical resection of 1-3 cerebral metastases and demonstrated an improvement in intracranial control but no corresponding improvement in overall survival.
17. Manon R, O'Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H, et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: An Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol. 2005;23(34):8870-6.
18. Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database of Systematic Reviews (Online). 2012;4:CD003869.
19. Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007;68(5):1388-95.
20. Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, et al. A European organisation for research and treatment of cancer phase iii trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: Quality-of-life results. J Clin Oncol. 2013;31(1):65-72.
21. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomized controlled trial. Lancet Oncol. 2009;10(11):1037-44. This study assessed the impact ofWBRT in patients treated with radiosurgery using a battery of validated neurocognitive function tests and demonstrated decrements in neurocognition at the pre-specified 4 month time point. Though small, the study has had a significant impact on the debate regarding the value of initial WBRT in patients with a limited number of brain metastases.
22. Langley RE, Stephens RJ, Nankivell M, Pugh C, Moore B, Navani N, et al. Interim data from the Medical Research Council QUARTZ Trial: Does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from nonsmall cell lung cancer? Clin Oncol. 2013;25(3): E23-30.
23. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary Report on the Graded Prognostic Assessment: An accurate and facile diagnosisspecific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419-25. This publication summarizes the diagnosis-specific prognostic tools which can be used to estimate survival after a brain metastasis diagnosis in the major primary tumor types.
24. Preusser M, Berghoff AS, Schadendorf D, Lin NU, Stupp R. Brain metastasis: Opportunity for drug development? Curr Op Neurol. 2012;25(6):786-94.
25. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-43.
26. Kuhn J, Robins HI, Mehta M, Fine H, Cloughesy T, Wen P, et al. Tumor sequestration of lapatinib (NABTC 04-01). Neuro Oncol. 2008;10(5): [Abstract ET-05].
27. Morikawa A, Peereboom DM, Smith QR, Thorsheim H, Lockman PR, Simmons AJ, et al. Clinical evidence for drug penetration of capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer. J Clin Oncol. 2013: [Abstract 514].
28. Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. 2012;29(3):770-81.
29. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26(12):1993-9.
30. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter phase II study of lapatinib in patients with brainmetastases fromHER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452-9. This is the largest prospective study to date evaluating the role of lapatinib in patients with HER2+ breast cancer brain metastases.
31. Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol. 2013;14(1):64-71. This study established the activity of lapatinib and capecitabine in the up-front treatment of patients with HER2+ breast brain metastases and is serving as the foundation for a potential phase III trial testing the role of systemic therapy in lieu of radiotherapy as initial treatment.
32. Lin NU, Eierman W, Greil R, Campone M, Kaufman B, Steplewski K, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neuro Oncol. 2011;105(3):613-20.
33. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib vs standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): A multi-center, open-label, randomized phase 3 trial. Lancet Oncol. 2012;13(3):239-46. This phase 3 study demonstrated that patients with EGFR mutations may be treated with erlotinib in lieu of cytotoxic chemotherapy.
34. Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer metastatic to the brain. Clin Cancer Res. 2012;18(4):938-44.
35. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crino L, Villa E. Gefitinib in patients with brain metastases from nonsmall-cell lung cancer: A prospective trial. Ann Oncol. 2004;15(7):1042-7.
36. Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in nonsmall cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012;77(3):556-60. This small non-randomized study describes a high level of efficacy ofEGFR tyrosine kinase inhibitors for brainmetastases in patients whose tumors carry EGFR activating mutations.
37. Wu YL, Zhou C, Cheng Y, Lu S, Chen GY, Huang C, et al. Erlotinib as second-line treatment in patients with advanced nonsmall-cell lung cancer and asymptomatic brain metastases: A phase II study (CTONG-0803). Ann Oncol. 2013;24(4):993-9.
38. Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, et al. Development of central nervous system metastases in patients with advanced nonsmall cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16(23):5873-82.
39. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from nonsmall-cell lung cancer. J Clin Oncol. 2013;31(7):895-902.
40. Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone vs WBRT and SRS with temozolomide or erlotinib for nonsmall cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys. 2013;85(5):1312-8.
41. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, et al. Response and resistance in a nonsmall-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol. 2006;24(27):4517-20.
42. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant nonsmall cell lung cancer. Neuro Oncol. 2011;13(12):1364-9.
43. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16. This is the pivotal trial leading to the approval of vemurafenib in melanoma.
44. Dummer R, Rinderknecht J, Goldinger SM, Wagner I, Mitchell L, Veronese ML, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol. 2011;29(Suppl): [Abstract 8548].
45. Rochet NM, Dronca RS, Kottschade LA, Chavan RN, Gorman B, Gilbertson JR, et al. Melanoma brain metastases and vemurafenib: Need for further investigation. Mayo Clin Proc. 2012;87(10):976-81.
46. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAFmutated metastatic melanoma: A multi-center openlabel, phase 3 randomized controlled trial. Lancet. 2012;380(9839):358-65. This is the pivotal trial leading to the approval of dabrafenib in melanoma.
47. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893-901.
48. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multi-center, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087-95.
49. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
50. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase II trial. Lancet Oncol. 2012;13(5):459-65.
51. Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 2013;23(3):191-5.
52. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012;117(2):227-33.
53. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16(1):269-78.
54. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, et al. Safety of bevacizumab in patients with nonsmall-cell lung cancer and brain metastases. J Clin Oncol. 2009;27(31):5255-61.
55. Labidi SI, Bachelot T, Ray-Coquard I, Mosbah K, Treilleux I, Fayette J, et al. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: A case series. Clin Breast Cancer. 2009;9(2):118-21.
56. Lu YS, Chen WW, Ling CH, Tseng LM, Yeh DC, Wu PF, et al. Bevacizumab, etoposide, and cisplatin (BEEP) in brain metastases of breast cancer progressing from radiotherapy: Results of the first stage of a multicenter phase II study. J Clin Oncol. 2012;30: [Abstract 1079].
57. Lin NU, Gelman R, Younger J, Sohl J, Freedman R, Sorensen AG, et al. Phase II Trial of Carboplatin (C) and Bevacizumab (BEV) in Patients (Pts) with Breast Cancer Brain Metastases (BCBM). J Clin Oncol. 2013;31: [Abstract 513].
58. De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, et al. Efficacy and safety of bevacizumab in active brain metastases from nonsmall cell lung cancer. J Neuro Oncol. 2010;100(3):443-7.
59. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib vs interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-24.
60. Gore ME, Hariharan S, Porta C, Bracarda S, Hawkins R, Bjarnason GA, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer. 2011;117(3):501-9.
61. Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, et al. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: Effectiveness, safety and treatment patterns in clinical practicebased on medical chart review. BJU Int. 2010;105(9):1247-54.
62. Lim ZD, Mahajan A, Weinberg J, Tannir NM. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy. Am J Clinl Oncol. 2013;36(3):258-60.
63. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-34.
64. Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller Jr WH, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010;116(5):1272-80.
65. Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol. 2010;21(5):1027-31.